CENTER FOR EMERGING TECHNOLOGIES
Current Tenant Summaries and Notable Graduates

Current Tenants _________________________________________________________
BioSynthema
Jack L. Erion, Ph.D.
President and CEO

BioSynthema develops receptor-targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Its technology is based on the combination of novel tissue-specific, receptor-targeted peptides, and chemically linked metal chelates to derive compounds that have radiodiagnostic imaging and radiotherapeutic applications. Its scientists collaborate with an international group of scientists and clinical researchers, including scientists at Washington University in St. Louis.

BioSynthema is developing a series of radionuclide-linked peptide diagnostic and therapeutic pair products, each targeted to a specific form of cancer and tumor type. This diagnostic/therapeutic pair approach represents a major advance over existing oncology products because it will allow physicians to use an in vivo diagnostic imaging agent to select patients most likely to respond to a corresponding radiotherapeutic.
_________________________________________________________

C2N logo
C2N Diagnostics, LLC
www.c2ndiagnostics.com
Tim West, Ph.D.
Director of
Laboratory Operations

C2N Diagnostics, LLC is commercializing proprietary and novel metabolic labeling technology that seeks to bridge the gap between Alzheimer’s Disease diagnosis and novel disease-modifying treatment. The approach uses in vivo stable isotope labeling to tag newly synthesized amyloid beta peptide in the cerebrospinal fluid, combined with mass spectrometry to detect the change in labeled amyloid over time. The rates of synthesis and degradation of beta amyloid are measured, providing previously unavailable insights into the state of Alzheimer’s Disease progression and how therapeutics can potentially modify the course of the disease.

Discovered at Washington University School of Medicine by Drs. Randy Bateman and David Holtzman, the technology was recognized by Scientific American as one of the top 50 scientific advancements in 2006. In conjunction with LifeTech Research, Inc of Baltimore, Maryland, Drs. Bateman and Holtzman founded C2N Diagnostics during late 2007.
_________________________________________________________

expo logo
Expo Technologies, LLC

(F.K.A. SpectrAlliance)
www.expoforpat.com
Susan L. Bragg, Ph.D.
Technical Director

Expo Technologies is an industry leader in the implementation of process analytical solutions for the pharmaceutical manufacturing industry. Expo designs, builds and implements spectroscopic instrumentation for pharmaceutical industrial process control. Its range of products is designed to analyze and monitor a process stream in real time. These instruments are used in a range of operations including powder blending, drying and reactor vessel cleaning.

Expo’s process control software products, NovaPAC© and NovaMath© provide ease of use while maintaining the security required by the Food and Drug Administration. The software features connectivity to a wide range of analytical instruments and simultaneous connectivity to the pharmaceutical manufacturer’s plant wide infrastructure.
_________________________________________________________

Kerios log
Kereos, Inc.

www.kereos.com
Robert A. Beardsley, Ph.D.
President and CEO

Kereos, Inc. is developing targeted therapeutics and imaging agents to improve the detection and treatment of cancer. Kereos’ targeted emulsions seek out highly specific molecular markers for disease, enabling earlier diagnosis and more effective treatment than previously possible.

Kereos’ first candidate, Kl-0001, will allow earlier detection - and thus diagnosis - of a wide variety of solid tumors using magnetic resonance Imaging (MRI). Building on this technology, Kereos is developing a targeted chemotherapeutic, KI-1001, which can be directed to the same molecular markers used for early tumor detection, thereby providing novel and potentially more effective options to treat a variety of cancers sooner.
_________________________________________________________

Lickenbrock logo
Lickenbrock Technologies, LLC
www.lickenbrock.com
Tim Holmes, D.Sc.
Chief Executive Officer

Lickenbrock Technologies is an independent research and development company that creates advanced image processing algorithms and associated software for customer companies and agencies in the medical and defense industries. At Lickenbrock, our work covers both ends of the research and development spectrum. Our research and development ranges from the inception of an idea, and the theoretical physical modeling of the system - to product deployment, maintenance and support to the customer’s sales force.

Lickenbrock develops products for the following technologies and applications:
• Image processing for medical and defense applications • Computed tomography • Automated measurements from images • Signal recovery, deconvolution, random signals • Optimization methods, inverse problems • Advanced software algorithms for optics • Graphical user interface development
_________________________________________________________

LynxESS logo
LynxESS, Inc.

www.lynxess.com
Nawaz Anwarudeen
Principal

LynxESS, Inc., Lynx Engineering Solutions & Services, Inc. provides automation, control, packaging, manufacturing IT, and FDA validation solutions and services.

The company designs, develops, integrates, installs, validates and supports projects for pharmaceutical, food and beverage, medical device, cosmetics and personal care manufacturers.
_________________________________________________________

Medros, Inc.
www.medrospharma.com
Thomas Baranski,MD, PhD
and Ross Cagan, PhD
Co-Founders

Rational drug delivery is constrained by the fact that pre-clinical modeling is expensive, time- consuming, and only weakly predictive of clinical results. Medros was developed by two professors from Washington University School of Medicine to utilize proprietary, high-throughput, and validated Drosophila-based disease models to screen for drug candidates. These proprietary models hold the promise of better safety and efficacy data than traditional pre-clinical modeling techniques and are quicker and less expensive.

Medros is focused on cancer and diabetes, serious and widespread diseases that represent two of the largest unmet needs in the medical marketplace.
_________________________________________________________

NVIDIA logo
NVIDIA

www.nvidia.com
Formerly AGEIA™ Technologies Inc.

Formerly AGEIA™ Technologies Inc. is dedicated to delivering dynamic interactive realism to the ever demanding complexity of next generation games. Its flagship solution, AGEIA PhysX™, is the world’s first dedicated physics engine and physics processor to bridge the gap between static virtual worlds and responsive unscripted physical reality. AGEIA PhysX™ allows developers to use active physics-based environments for a truly realistic entertainment experience.
_________________________________________________________
Orion logo
Orion Genomics
www.oriongenomics.com
Nathan Lakey
President and CEO

Orion Genomics is the Second Code™ Company. For six years, Orion has successfully commercialized products based on the “Second Code” of epigenetic DNA methylation, and is now poised to extend its offerings to the oncology molecular diagnostic market. Our mission is to understand and commercialize epigenetics in human disease. Orion Genomics has trademarked the term “Second Code” to generally describe epigenetic information. Epigenetics refers to changes to DNA that are not attributable to changes in DNA sequence (i.e., changes in the “First Code”).

The principal epigenetic mechanism in higher organisms is DNA methylation, where DNA is chemically modified in a stable, heritable way by the addition of a methyl group to one of the bases of DNA. Orion is combining its substantial intellectual property estate in DNA methylation with recent discoveries that link DNA methylation with cancer. Therefore, Orion focuses on determining the state of DNA methylation to be incorporated into novel early cancer detection molecular diagnostics tests.
_________________________________________________________

Pepex Biomedical, Inc.
www.pepex-biomed.com
Steve Collins
President

Pepex Biomedical, Inc. is a medical device company. The company develops unique electrochemical biosensors that can potentially measure lactate, glucose, oxygen, carbon dioxide, pH and other metabolic analytes at the cellular level in human subjects. The miniaturized biosensor can be placed subcutaneously or used ex-vivo for continuous monitoring.

The company has a profoundly comprehensive patent estate which protects its novel technology worldwide. Pepex’s advanced sensor designs provide a platform technology which makes it well suited as an electrochemical assay with broad utility as a medical device.
_________________________________________________________

ppl Devices, LLC
Dave Reini
President
ppl Devices, LLC is a new company founded by an employee of two previous CET based startups. ppl Devices is focused on the next step in connecting people, enabled by recent advancements in video technology, through web based wireless devices.
_________________________________________________________
Singulex logo
Singulex, Inc.

www.singulex.com
Philippe Goix, Ph.D.
President

Singulex, Inc., is committed to advancing life science research and clinical diagnostics through the application of its ultrasensitive instrumentation and assays. Singulex Direct Molecular Detection technology enables faster, simple and precise, low volume detection of specific unamplified molecules in small sample volumes solution, despite large backgrounds of non-target molecules.

The company’s ultrasensitive instrumentation is targeted to research and clinical applications in biomarker analysis and drug development
_________________________________________________________

Somark logo
Somark Innovations Inc.

www.somarkinnovations.com
Ramos M. Mays
Mark C. Pydynowski

Somark is a St. Louis based tech company that is developing a patented ID system based on a RFID Bio-Ink Tattoo. When applied, the ink creates a unique ID that can be detected without line of sight. The technology will be initially applied to the livestock industry to help identify and track cattle.

Somark’s goals are to 1) ensure a safe food supply and 2) prevent export trade loss from food animal disease scares, e.g. BSE (a.k.a. Mad Cow Disease).
_________________________________________________________

TradeHarbor logo
TradeHarbor, Inc.
www.tradeharbor.com
Paul S. Heirendt
President & CEO

TradeHarbor’s Voice Signature ServiceSM offering (VSS) enables trusted interactions through strong authentication. 

The VSS uses voice biometrics in a managed service to strongly authenticate individuals over the telephone and Internet, combating fraud and identity theft and producing operational savings via more convenient/efficient authentication, compared to the use of passwords, PIN’s and knowledge-based authentication.

TradeHarbor’s unique “signature” approach also provides legally-binding remote signatures for telephone and online transactions.  Initial target markets include healthcare and financial services (including credit card issuers and merchants, brokerage services, mortgage origination, etc.).  TradeHarbor’s vision is for the VSS to become the global standard for consumer authentication over the telephone and Internet.
_________________________________________________________

VirRx logo
VirRx, Inc.

www.virrx.com
Drew Lichtenstein, Ph.D.
Program Director

VirRx, Inc. is a biotechnology company built around the expertise of its founder, Dr. William S. M. Wold, and his colleagues at Saint Louis University. The primary mission of VirRx is to design, construct, and evaluate genetically-engineered adenovirus “vectors” for use as drugs to treat human cancer.

In VirRx’s program, genetic alterations are made in Ad5 such that following injection of the virus vector into a tumor, the vector will infect the tumor cells and replicate in the cells causing tumor cell destruction until the entire tumor is destroyed. The vector replicates preferentially in tumor cells as compared to non-tumor cells, so toxic side-effects are expected to be minimal. VirRx has constructed and evaluated multiple adenovirus vectors with different properties.

VirRx and collaborator Introgen have selected one vector, named INGN 007, to advance to a Phase I clinical trial for cancer expected to begin in 2008. The secondary mission of VirRx is to exploit its expertise in adenovirus technology to conduct contract research and development.
_________________________________________________________

Notable CET graduates _________________________________________________________

Exegy provides the power to process data at extreme speeds, producing valuable insight faster than ever before. Because Exegy’s appliances are based on hardware acceleration, more knowledge can be delivered faster without increasing operating costs, space requirements or management time.

Exegy’s mission is to accelerate the creation of knowledge by transforming the way the world computes..
_________________________________________________________

Stereotaxis logo
Stereotaxis
www.stereotaxis.com

Stereotaxis’ comprehensive range of proprietary products and solutions, which are built around the technology of magnetics, have introduced a new era in cardiac interventional medicine. This era is one in which physicians are able to safely and remotely perform computerized catheter-based interventional procedures. Physicians are able to conduct these procedures using a range of “point and click”, “joystick”, “push button” and “touch screen” modes, from the control room adjacent to the patient lab, or cath lab, and outside the x-ray field that is used for all types of interventional procedures.

Physicians may use partial or full automation of procedure protocols through the use of customized software. Products are designed to provide patients with enhanced outcomes, safety and access to important new therapies, as well as to improve hospital’s cath lab efficiencies and to improve physician safety, comfort and ease of use relative to conventional interventional methods.
_________________________________________________________

6/01/2008